The amount of milestone payment received upon achieving performance obligation.

No definition available.

Name:	ird_FirstMilestonePaymentReceived
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The maximum amount funded to support the study.

+ References

No definition available.

+ Details

Name:	ird_MaximumAmountFundedToSupportStudy
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone payments receivable upon the achievement of development, regulatory and commercial goals.

+ References

No definition available.

+ Details

Name:	ird_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The maximum percentage of tiered royalties receivable based on the aggregate annual net sales of all Nyxol Products in the United States.

+ References

No definition available.

+ Details

Name:	ird_MaximumPercentageOfTieredRoyaltiesReceivable
Namespace Prefix:	ird_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of milestone payment met by the entity which required FDA's approval.

+ References

No definition available.

+ Details

Name:	ird_MilestonePaymentRequiredUnderFDASApproval
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of milestone payment received upon achieving performance obligation..

+ References

No definition available.

+ Details

Name:	ird_MilestonePaymentsAmountReceived
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Non-cancellation period of constraint for Recognizing Research and Development Revenue, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	ird_NonCancellationPeriodOfConstraintForResearchAndDevelopmentRevenue
Namespace Prefix:	ird_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of non-refundable cash payments received during the period under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ird_NonRefundableCashPaymentReceived
Namespace Prefix:	ird_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number of performance obligations in accordance with the provisions under ASC 606, the Company identified.

+ References

No definition available.

+ Details

Name:	ird_NumberOfPerformanceObligations
Namespace Prefix:	ird_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=ird_ViatrisLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_HealthCareOrganizationRevenueSourcesAxis=ird_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ird_BioSenseLicenseAndAssignmentsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ird_SBIRGrantAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ird_RDH12AgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Revenue and Other Funding Agreements - Additional Information (Details) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 10, 2020 USD ($)	Nov. 30, 2022 USD ($) obligation	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jul. 22, 2025 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and collaborations revenue			$ 755	$ 2,882	$ 2,912	$ 7,252
Viatris License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable cash payment received		$ 35,000
Maximum amount of payments receivable for development, regulatory and commercial milestones		$ 130,000
First milestone payments received								$ 10,000
Maximum percentage of tiered royalties receivable		20.00%
Number of distinct performance obligations \| obligation		2
Non-cancellation period of Constraint for Research and Development Revenue		120 days
License and collaborations revenue			800	2,900	2,912	7,252
Viatris License Agreement \| Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and collaborations revenue					0
Milestone payment requirements attributed to the FDA's approval									$ 10,000
BioSense License and Assignments Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum amount of payments receivable for development, regulatory and commercial milestones	$ 84,500
Milestone payments received					0
SBIR Grant Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and collaborations revenue			500	200	700	200
Milestone payments received				900
RDH12 Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License and collaborations revenue			$ 600	$ 0	$ 800	$ 0
Maximum amount of loan							$ 1,600